Squarepoint’s SELLAS Life Sciences SLS Stock Holding History

Squarepoint’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155K	Sell	10,512 -64,239	-86%	-$443K	﹤0.01%	4124
2026 Q1	$316K	Buy	74,751 +61,466	+463%	+$275K	﹤0.01%	3664
2025 Q4	$50.1K	Sell	13,285 -32,895	-71%	-$63.9K	﹤0.01%	4130
2025 Q3	$74.3K	Buy	46,180 +30,058	+186%	+$53.5K	﹤0.01%	4168
2025 Q2	$35.3K	Buy	+16,122	New	+$24.7K	﹤0.01%	4349
2021 Q1	–	Sell	-10,081	Closed	-$59K	–	3567
2020 Q4	$59K	Buy	+10,081	New	+$40.3K	﹤0.01%	2792
2020 Q3	–	Sell	-32,406	Closed	-$95K	–	2816
2020 Q2	$95K	Buy	+32,406	New	+$87.9K	﹤0.01%	2024
2019 Q4	–	Sell	-1,207	Closed	-$7K	–	2770
2019 Q3	$7K	Buy	+1,207	New	+$8.89K	﹤0.01%	2284
2017 Q3	–	Sell	-14	Closed	-$12K	–	1856
2017 Q2	$12K	Buy	+14	New	+$12.2K	﹤0.01%	1490

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint's SLS Position: Q2 2026 in Review

Squarepoint reduced its SELLAS Life Sciences (SLS) stake by 86% in Q2 2026, selling an estimated $443K and leaving 10,512 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

Squarepoint first reported a position in SLS in Q2 2017 and has held it in 9 quarters since. The position peaked at $316K in Q1 2026. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Squarepoint held 10,512 shares of SELLAS Life Sciences worth $155K as of Q2 2026.
Squarepoint sold 64,239 SELLAS Life Sciences shares in Q2 2026, an estimated $443K.
SELLAS Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4124 holding.
Squarepoint first reported a position in SELLAS Life Sciences in Q2 2017 and has held it in 9 quarters since.
Squarepoint's SELLAS Life Sciences position peaked at $316K in Q1 2026.
193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.